ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/paediatric-and-aya/lymphoma-and-leukaemias
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Lymphoma and Leukaemias
27
trial(s) found.
NCT07354074
Paed
Phase 2
Recruiting
A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation (
CABL001I12202
)
BCR-ABL1 inhibitor
Chronic myelogenous leukaemia
Leukaemia
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07306832
Paed
Phase 1
Recruiting
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) (
M25-692
)
Acute myeloid leukaemia
WA
6009 - Perth - Perth Children's Hospital
NCT07109219
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia (
ALLight
)
anti-CD22 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06137144
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies (
PRIMAVERA
)
PRMT5 inhibitor
PRMT5 inhibitor,MTA-co-operative
Lymphoma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.8011 - Christchurch - Christchurch Children's Hospital
NCT05269771
Paed
No longer available
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV) (
CINC424B2002I
)
JAK1/JAK2 inhibitor
Polycythemia vera
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
anti-CD33 antibody-drug conjugate
antimetabolite
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04870944
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04293562
Paed
Phase 3
Recruiting
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (
AAML1831
)
anti-CD33 antibody-drug conjugate
liposomal cytarabine/daunorubicin
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03601442
Paed
Available
Managed Access Programs for CTL019, Tisagenlecleucel (
CCTL019B2003I
)
autologous CAR-T-cell therapy,CD19-targeting
Leukaemia
Lymphoma
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
NCT03409081
Paed
No longer available
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (
2215-CL-9200
)
AXL/FLT3 inhibitor
Acute myeloid leukaemia
ACT
2605 - Garran - The Canberra Hospital
NCT02724163
Paed
Phase 3
Recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (
Myechild01
)
anti-CD33 antibody-drug conjugate
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12625001195448
Paed
Phase 1
Not yet recruiting
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (
PLATYPS
)
B-cell lymphoma
Leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12621000246886
Paed
Phase 2
Not yet recruiting
AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. (
AMLM22-D3
)
BRD4 inhibitor
Acute myeloid leukaemia
NCT02670564
Paed
Phase 4
Unknown
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) (
NZ-2015-069--ZH-2014-0535
)
Busulfan
Treosulfan
alkylating agent
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (21)
No longer available (2)
Not yet recruiting (2)
Unknown (1)
Recruitment Country and State
WA (14)
QLD (13)
VIC (13)
NSW (11)
SA (5)
NZ (4)
ACT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (8)
Phase 2 (6)
Phase 2 / Phase 3 (1)
Phase 3 (4)
Phase 4 (2)
Trial Type
Paed (27)
Cancer Therapy Class
CD19
19%
CD20
15%
CD33
11%
BCR-ABL1
7%
cereblon
7%
AXL
7%
FLT3
7%
CD22
4%
BTK
4%
CD7
4%
ROR1
4%
PD-1
4%
PD-1/PD-L1
4%
PRMT5
4%
KIT
4%
PDGFRA
4%
SRC
4%
YES1
4%
IL-6
4%
JAK1
4%
JAK2
4%
Bcl2
4%
DNA methyltransferase
4%
CD79b
4%
FACT complex
4%
KMT2A
4%
ALK
4%
ROS1
4%
TRK
4%
proteasome
4%
BRD4
4%
Facility
6009 - Perth - Perth Children's Hospital (9)
4101 - South Brisbane - Queensland Children's Hospital (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
2031 - Randwick - Sydney Children's Hospital (6)
3052 - Parkville - Royal Children's Hospital Melbourne (5)
2145 - Westmead - The Children's Hospital at Westmead (5)
NZ.1023 - Grafton - Starship Children's Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2305 - New Lambton Heights - John Hunter Children's Hospital (2)
3168 - Clayton - Monash Children's Hospital (2)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (2)
6000 - Perth - Royal Perth Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.8011 - Christchurch - Christchurch Children's Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4215 - Southport - Gold Coast University Hospital (1)
2605 - Garran - The Canberra Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Lymphoma
Lymphoid leukaemia
Acute lymphoblastic leukaemia
Myeloid leukaemia
Non-Hodgkin's lymphoma
Acute myeloid leukaemia
B-cell malignancy
Mature B-cell malignancy
B-cell acute lymphoblastic leukaemia/lymphoma
B-cell lymphoma
Neurological cancer
Solid tumour
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Central nervous system cancer
Chronic leukaemia
Chronic myelogenous leukaemia
Chronic lymphocytic leukaemia
T-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Burkitt lymphoma
Ewing family of tumours
Ewing sarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Primitive neuroectodermal tumour
Sarcoma
Peripheral T-cell lymphoma
T-cell lymphoma
Mixed phenotype acute leukaemia
Myeloproliferative neoplasm
Polycythaemia vera
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy